Ultimately, the biotech hopes the agency will change its interpretation of the law so that drugmakers would be encouraged to develop more fixed-dose combination drugs.

FORBES: Gilead Challenges FDA Over Exclusivity For Its Latest AIDS Drug

In its petition, the biotech notes that the FDA has denied exclusivity to 10 fixed-dose combination drugs containing both new and previously approved active moieties for nearly 20 years.

FORBES: Gilead Challenges FDA Over Exclusivity For Its Latest AIDS Drug

The biotech wants the agency to change the way it grants exclusivity to fixed-dose combination drugs and hopes to win its argument so that more revenue can be wrung out of its recently approved Stribild HIV treatment.

FORBES: Gilead Challenges FDA Over Exclusivity For Its Latest AIDS Drug